Pfizer: positive results for pneumococcal vaccine
(CercleFinance.com) - Pfizer today announced positive top-line results from a pivotal US Phase 3 study of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by all 20 serotypes of Streptococcus pneumoniae (pneumococcus) in infants.
Pfizer reports that all 20 serotypes showed functional robustness (OPA) and increased antibody responses after the fourth dose, supporting the potential benefit of all serotypes in this 20-valent vaccine candidate.
Encouraged by the data, which, if approved for a pediatric indication, 20vPnC would have the potential to cover more of the remaining clinically significant burden of childhood pneumococcal disease than any other available pneumococcal conjugate vaccine, it said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.